Nephros (NEPH) Cash & Equivalents (2010 - 2026)

Nephros' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $4.0 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 1.54% year-over-year to $4.0 million in Q1 2026; TTM through Mar 2026 was $4.0 million, a 1.54% decrease from a year earlier, with the FY2025 full-year figure at $5.4 million, up 43.62% from the prior year.
• Cash & Equivalents eased to $4.0 million in Q1 2026 per NEPH's latest filing, from $5.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $5.4 million in Q1 2022 and bottomed at $2.5 million in Q3 2024.
• The 5-year median for Cash & Equivalents is $4.1 million (2023), against an average of $4.2 million.
• Across the five-year window, Cash & Equivalents plunged 49.52% in 2022 and surged 110.46% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $3.6 million in 2022, then gained by 18.52% to $4.3 million in 2023, then dropped by 12.7% to $3.8 million in 2024, then soared by 43.62% to $5.4 million in 2025, then dropped by 25.59% to $4.0 million in 2026.
• Per Business Quant, the three latest NEPH Cash & Equivalents figures stand at $4.0 million (Q1 2026), $5.4 million (Q4 2025), and $5.2 million (Q3 2025).